eltrombopag

Eltrombopag is an oral small-molecule thrombopoietin receptor agonist developed by Ligand Pharmaceuticals and GSK and later commercialized by Novartis as Promacta and Revolade. It binds the transmembrane domain of the thrombopoietin receptor and stimulates megakaryocyte proliferation and differentiation, increasing platelet production. The drug is primarily used for thrombocytopenic disorders, especially chronic immune thrombocytopenia, and has also been developed and used in severe aplastic anemia and thrombocytopenia associated with chronic hepatitis C. Beyond its hematology use, publications cited in the provided context describe experimental anticancer and iron-chelation related effects, including inhibition of HuR-dependent tumor biology and antiproliferative activity in leukemia models, but these are not established marketed indications.

Brand names

PromactaRevolade

Other names

eltrombopag olamine艾曲波帕